You searched for "retention"
So you want to be a urologist?
Urology is a varied, innovative and friendly speciality and it is easy to see why so many people are attracted to it. The article below is designed to help all doctors wishing to apply for an ST3 post get the...Francisco Díaz (1527-1590), forefather of urology
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). We often talk about urology being the oldest surgical specialty and discuss the...Intravesical GAG replacement therapies for bladder pain syndrome / interstitial cystitis – an update
The barrier function of the glycosaminoglycan (GAG) layer of the urothelium was identified by Parsons in 1975, and intravesical therapies to treat chronic inflammatory conditions of the bladder were developed soon after. However, the active role of the urothelium in...Frailty in urology – part 1
Part 2 of this topic can be found here Statement of the problem Clinical frailty carries an increased risk of poor health outcomes. The pathological process resulting in frailty is often overlooked and elucidating its aetiology and natural history are...BAUS Annual Scientific Meeting 2024
Day 1 Toni Huw Mihailidis and Mriganka Mani Sinha Another year and another brilliant meeting in which urologists from the UK and around the globe assembled for a highly entertaining event. Day one kicked off with a topical and ever-pervasive...
Underactive Bladder
This book is an excellent update on the concept of the underactive bladder. The authors and editors led by Chris Chapple address some of the controversies surrounding definitions, diagnosis and treatment. The International Continence Society (ICS) currently defines detrusor overactivity...Ambulatory local anaesthetic implantation of percutaneous sacral nerve stimulators
Background The current treatment paradigm for detrusor overactivity (DO) and dysfunctional voiding (DV) includes conservative measures, pharmacotherapy, intravesical onabotulinum toxin A (Botox®), sacral nerve modulation (SNM / SNS) and urinary diversion as a last resort [1]. Incidence of DO is...
The EP2 receptor – a novel target for prostate cancer?
This basic science paper sets out to evaluate the effects that celecoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor, have on prostate cancer cell lines and evaluated the mechanisms behind these effects. COX-2 induces the production of prostaglandins, which promote cell proliferation...
